This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Covetrus Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

-7.8%

Tasa de crecimiento de los beneficios

-9.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.5%
Tasa de crecimiento de los ingresos	7.1%
Rentabilidad financiera	-0.9%
Margen neto	-0.3%
Última actualización de beneficios	30 Jun 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line

Aug 04

Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders

Jun 02

Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

May 02

Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

Jan 07

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Oct 21

An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

Sep 16

Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain

Dec 18

Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 12

Covetrus Q3 2020 Earnings Preview

Nov 09

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Covetrus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:CVET Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 22	4,649	-13	723
31 Mar 22	4,621	-40	728
31 Dec 21	4,575	-54	714
30 Sep 21	4,575	-56	709
30 Jun 21	4,539	-90	714
31 Mar 21	4,376	-13	685
31 Dec 20	4,339	-26	698
30 Sep 20	4,225	-19	700
30 Jun 20	4,117	-940	630
31 Mar 20	4,100	-996	688
31 Dec 19	3,976	-980	661
30 Sep 19	3,871	-948	576
30 Jun 19	3,776	27	587
31 Mar 19	3,772	65	504
29 Dec 18	3,778	101	485
30 Sep 18	3,791	69	547
30 Jun 18	3,776	74	543
31 Mar 18	3,649	67	532
30 Dec 17	3,580	64	460
31 Dec 16	3,353	70	489
26 Dec 15	2,978	60	418

Ingresos de calidad: CVET is currently unprofitable.

Margen de beneficios creciente: CVET is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CVET is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.

Acelerando crecimiento: Unable to compare CVET's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: CVET is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (1.9%).

Rentabilidad financiera

Alta ROE: CVET has a negative Return on Equity (-0.85%), as it is currently unprofitable.

This company has been acquired

Covetrus Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2022 earnings: EPS misses analyst expectations

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS misses analyst expectations

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Recent updates

Covetrus, Inc. Files Form 15

Covetrus, Inc.(NasdaqGS:CVET) dropped from NASDAQ Composite Index

Covetrus Announces the Appointment of Michelle Bonfilio as Chief People Officer

Insider exercised options and sold US$185k worth of stock

Covetrus Appoints Margie B. Pritchard as General Counsel and Corporate Secretary

President notifies of intention to sell stock

Covetrus, Inc. Announces Retirement of Matthew Foulston as Executive Vice President, Effective December 31, 2022

Saxena White P.A. Announces Settlement of Class Action on Behalf of Purchasers of Covetrus, Inc. Common Stock

Second quarter 2022 earnings: EPS misses analyst expectations

Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

President exercised options and sold US$196k worth of stock

President notifies of intention to sell stock

Key Executive exercised options and sold US$162k worth of stock

Independent Director recently sold US$709k worth of stock

President notifies of intention to sell stock

Executive VP & Global CFO exercised options and sold US$259k worth of stock

Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders

Price target increased to US$23.00

Clayton, Dubilier & Rice, LLC and TPG Global, LLC offered to acquire remaining 75.8% stake in Covetrus, Inc. (NasdaqGS:CVET) $2.2 billion.

Price target decreased to US$21.40

First quarter 2022 earnings: EPS misses analyst expectations

Covetrus® Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

President exercised options and sold US$149k worth of stock

Covetrus, Inc., Annual General Meeting, May 11, 2022

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

CEO, President & Director exercised options and sold US$111k worth of stock

Chief Administrative Officer exercised options and sold US$121k worth of stock

Covetrus, Inc. Announces the Launch of Covetrus Pulse

Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?

CEO, President & Director notifies of intention to sell stock

Price target decreased to US$28.60

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.34 loss in 3Q 2020)

CEO, President & Director exercised options and sold US$193k worth of stock

We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt

Chief Administrative Officer exercised options and sold US$229k worth of stock

An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued

VP, Chief Accounting Officer & Global Controller Laura Phillips has left the company

Director recently bought US$116k worth of stock

Price target decreased to US$31.33

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.41 profit in 2Q 2020)

Covetrus, Inc. (NasdaqGS:CVET) entered into a definitive agreement to acquire VCP.

CEO, President & Director notifies of intention to sell stock

Covetrus Enhances to Their Practice Management Software to Help Veterinary Clinics Compete Online and Deliver More Complete Healthcare

Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)

CEO, President & Director notifies of intention to sell stock

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.26 loss in 1Q 2020)

Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation

Is Covetrus (NASDAQ:CVET) Using Too Much Debt?

Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents

CEO, President & Director exercised options and sold US$277k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently sold US$203k worth of stock

Covetrus, Inc. Announces the Addition of Stacey M.M. Shirra as Vice President of Global Talent Management

Insider exercised options and sold US$59k worth of stock

Full year 2020 earnings released: US$0.16 loss per share (vs US$9.52 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?

Covetrus Appoints Link Welborn as Chief Veterinary Officer

Covetrus, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Covetrus Appoints Deborah Sharkey as Chief Consumer Officer

New 90-day high: US$39.89

Chief Administrative Officer notifies of intention to sell stock

Covetrus, Inc.(NasdaqGS:CVET) dropped from Russell 1000 Growth-Defensive Index

Desglose de ingresos y gastos
Beta